Navigation Links
Safer, cheaper building blocks for future anti-HIV and cancer drugs
Date:7/3/2014

A team of researchers from KU Leuven, in Belgium, has developed an economical, reliable and heavy metal-free chemical reaction that yields fully functional 1,2,3-triazoles. Triazoles are chemical compounds that can be used as building blocks for more complex chemical compounds, including pharmaceutical drugs.

Leveraging the compound's surprisingly stable structure, drug developers have successfully used 1,2,3-triazoles as building blocks in various anti-HIV, anti-cancer and anti-bacterial drugs. But efforts to synthesize the compound have been hampered by one serious hurdle: they depend on harmful heavy metals to work, and this severely limits their biological applications.

In new experiments reported in the journal Angewandte Chemie, Dr. Joice Thomas, Prof. Dr. Wim Dehaen and their team at KU Leuven's Molecular Design and Synthesis lab confirm for the first time that 1,2,3-triazoles can be synthesized through a metal-free, three-component reaction using readily available ingredients.

"We were able to develop a reaction that provided a good yield, high regioselectivity and easy access to diversely functionalized 1,2,3-triazoles," says corresponding author Prof. Dr. Wim Dehaen. "In other words, the reaction produces plenty of the compounds we're looking for, does so reliably without unwanted or unexpected outcomes, and does this in a way that makes it easy for us to isolate the compound. This makes our method highly desirable."

"Moving forward, we will focus on expanding the chemistry developed here to other new reactions while also exploring their possible applications in pharmaceutical as well as supra-molecular sciences," says lead author Dr. Joice Thomas.


'/>"/>

Contact: Wim Dehaen
wim.dehaen@chem.kuleuven.be
32-163-27439
KU Leuven
Source:Eurekalert

Page: 1

Related biology news :

1. New class of nanoparticle brings cheaper, lighter solar cells outdoors
2. Shifting evolution into reverse promises cheaper, greener way to make new drugs
3. Now it will become cheaper to make second-generation biofuel for our cars
4. A quicker, cheaper way to detect staph in the body
5. Iron-based process promises greener, cheaper and safer drug and perfume production
6. New method to diagnose sepsis is faster, cheaper
7. Novel LEDs pave the way to cheaper displays
8. Team uses forest waste to develop cheaper, greener supercapacitors
9. A route for steeper, cheaper, and deeper roots
10. Breakthrough could lead to cheaper, more sustainable chemical production
11. Waste cooking oil makes bioplastics cheaper
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... replacement at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica ... technology and host a hands-on workshop for surgeons to experience the simplicity of ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... endeavors to bring to market a pioneering medical device for the treatment of ... an engagement contract with Emergo, a global regulatory consultancy that helps companies like ...
(Date:1/21/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, today presented data from two clinical ... 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers ... In a Phase Ib/II study of napabucasin ... cancer stemness pathways by targeting STAT3 – colorectal cancer ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
Breaking Biology Technology: